Updated:
BioIntelliSense
BioIntelliSense supplies hospitals and post-acute providers with the BioButton wearable continuous vital-sign monitoring system.
BioIntelliSense
BioIntelliSense markets the BioButton system, a wearable device that continuously collects and analyzes vital signs and biometric measurements for patients in hospitals and at home. The company's website references peer-reviewed studies to support claims that comprehensive monitoring reduces ICU admissions, rapid response calls, and length of stay (per BioIntelliSense, citing Churpek et al., 2016; Weller et al., 2024). The technology includes the BioButton wearable, flexible gateways (mobile app, cellular, or Wi-Fi hubs), and the BioDashboard exception management software. BioIntelliSense targets both in-hospital and post-acute care settings, with a Rural Health Transformation program to streamline adoption for eligible providers. The company's operational footprint centers on Golden, Colorado (Altss estimate). The company does not publicly disclose the names of its leadership team, ownership structure, or funding sources. BioIntelliSense states it works exclusively with healthcare providers, not direct consumers. No recent activity has been disclosed beyond the January 2025 publication of research on earlier clinical emergency response activation (Altss research). BioIntelliSense's fundamental differentiator is its focus on a single integrated hardware-software platform for continuous monitoring, rather than offering a broader portfolio of medical devices or SaaS. The company relies on published clinical evidence to validate outcomes, a tactic more common among later-stage health-tech firms than early-stage device startups. Its current ownership and capital structure remain undisclosed.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Golden
Corporate office
Golden, CO, United States
Sector focus
Frequently asked questions
Who leads BioIntelliSense?
BioIntelliSense does not publicly name its CEO or executive team. The company's website and public filings list no individuals in leadership roles. This contrasts with many health-tech firms that highlight founder or executive backgrounds.
How does BioIntelliSense generate revenue?
BioIntelliSense sells or licenses the BioButton system—hardware, software, and monitoring service—to hospitals, health systems, and post-acute care organizations. The company does not offer direct-to-consumer sales, per its website.
Does BioIntelliSense have venture capital or other institutional investors?
BioIntelliSense has not disclosed any institutional investors, venture capital rounds, or debt financing. Its ownership structure is unknown. This opacity is unusual for a company marketing clinical-trial-level outcomes.
What published evidence supports BioIntelliSense's clinical claims?
BioIntelliSense's website cites several peer-reviewed studies, including research from Houston Methodist published in the Journal of Clinical Medicine (Weller et al., 2024) and a before-and-after study in the British Journal of Anaesthesia (Eddahchouri et al., 2022). The company also references internal analyses from American Health Network and Houston Methodist Hospital.
Is BioIntelliSense structured as a medical device company or a healthcare SaaS firm?
BioIntelliSense appears to operate as a combination medical-device manufacturer (the BioButton wearable) and healthcare software provider (the BioDashboard analytics platform). Its business model includes both hardware sales and recurring software/service revenue, though exact splits are undisclosed.
How does BioIntelliSense's solution differ from standard telemetry or spot-check monitoring?
BioIntelliSense claims that continuous monitoring via the BioButton, compared to intermittent manual vital checks, reduces ICU transfers, rapid response activations, and hospital stays (per studies cited by the company). The system also transitions from in-hospital to home use, a feature not common with traditional telemetry.
Does BioIntelliSense have a philanthropic or nonprofit arm?
BioIntelliSense has not disclosed any philanthropic or nonprofit entity. The for-profit company focuses on commercial sales to healthcare providers. No foundation or charitable structure has been publicly identified.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: